{"id":194640,"date":"2025-09-02T17:17:13","date_gmt":"2025-09-02T17:17:13","guid":{"rendered":"https:\/\/www.europesays.com\/us\/194640\/"},"modified":"2025-09-02T17:17:13","modified_gmt":"2025-09-02T17:17:13","slug":"chronic-gout-market-to-witness-strong-growth-by-2034-owing-to-the-expected-launch-of-therapies-including-mtor-inhibitors-and-urat1-inhibitors","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/194640\/","title":{"rendered":"Chronic Gout Market to Witness Strong Growth by 2034 Owing to the Expected Launch of Therapies including mTOR Inhibitors and URAT1 Inhibitors"},"content":{"rendered":"\n

Key Factors Driving the Growth of the Chronic Gout Market\u00a0<\/b><\/a><\/p>\n

Rising Chronic Gout Prevalence Linked to Lifestyle Changes<\/b><\/p>\n

The global incidence of gout has been increasing, with over 53 million<\/b> cases reported in 2024. The prevalence of gout among US adults is 3.9%<\/b>, with a higher burden in men at 5.2%<\/b> and in women at 2.7%.<\/b> This surge is attributed to lifestyle factors such as poor diet, excessive alcohol consumption, and obesity, which elevate uric acid levels and contribute to the development of chronic gout.<\/p>\n

Emergence of New Drug Classes in Chronic Gout\u00a0<\/b><\/p>\n

The chronic gout market is expected to surge, primarily driven by the development of mTOR<\/b> inhibitors,<\/b> such as NASP (Sobi\/Cartesian Therapeutics), and URAT1<\/b> inhibitors,<\/b> including Pozdeutinurad (Arthrosi Therapeutics) and Lingdolinurad (Atom Therapeutics).<\/p>\n

Launch of Emerging Chronic Gout Therapies in Forecast Period (2025-2034)<\/b><\/p>\n

The anticipated launch of emerging chronic gout therapies such as NASP (Sobi\/Cartesian Therapeutics), pozdeutinurad (Arthrosi Therapeutics), lingdolinurad (Atom Therapeutics), and others during the forecast period (2025-2034) will propel the chronic gout market.<\/p>\n

Increasing Awareness and Early Diagnosis<\/b><\/p>\n

There is a growing emphasis on patient education and self-management programs, which focus on lifestyle modifications, dietary changes, and the importance of adhering to medication. These initiatives are gaining traction and are expected to contribute to the market’s growth by promoting early diagnosis and preventive management of chronic gout.<\/p>\n

\"\" <\/p>\n

Chronic Gout Market Analysis<\/b><\/p>\n

The current treatment options for chronic gout, including allopurinol, febuxostat, and probenecid, are available as generics, providing widely accessible and cost-effective options for long-term urate-lowering therapy. In contrast, KRYSTEXXA (pegloticase) is a branded, FDA-approved biologic indicated explicitly for adults with chronic gout that is refractory to conventional treatments. KRYSTEXXA is a PEGylated, uric acid\u2013specific enzyme administered intravenously, which works by converting uric acid into allantoin, aa more soluble compound that is easily excreted, effectively reducing serum urate levels in patients whose gout remains uncontrolled despite standard therapy. Supporting its position in the rare disease space, Amgen acquired Horizon Therapeutics in October 2023 in a deal valued at approximately USD 27.8 billion, thereby expanding its portfolio. KRYSTEXXA itself has achieved key regulatory milestones, including FDA approval for gout treatment in September 2010 and, more recently, an expanded label in July 2022 allowing co-administration with methotrexate for patients with uncontrolled gout.<\/p>\n

Learn more about the chronic gout treatment options @ Chronic Gout Treatment Guidelines<\/b><\/a><\/p>\n

Chronic Gout Competitive Landscape<\/b><\/p>\n

Companies such as\u00a0 Sobi, Cartesian Therapeutics, Arthrosi Therapeutics, Atom Therapeutics<\/b>, and others are actively working in the chronic gout clinical trial landscape with their lead assets. A few of the emerging therapies, such as NASP, pozdeutinurad, and lingdolinurad<\/b>, among others, are currently in chronic gout clinical trials to improve the treatment landscape.<\/p>\n

NASP (nanoencapsulated sirolimus plus pegadricase) <\/b>by Sobi\/Cartesian Therapeutics<\/b> is an innovative, once-monthly investigational therapy for the treatment of chronic refractory gout. It is designed to lower serum urate levels and reduce tissue urate deposits, which, if left untreated, can cause gout flares and joint deformities. In July 2024, Sobi initiated a rolling Biologics License Application (BLA) submission to the US FDA for NASP (formerly SEL-212), supported by pivotal data from the DISSOLVE I and II trials, with a regulatory decision expected in 2026. This milestone follows the FDA’s granting of Fast Track designation to NASP in March 2024, underscoring the need for new treatments for chronic, refractory gout. Since July 2020, Sobi has held the rights to develop, register, and commercialize NASP outside China under a licensing agreement with Cartesian Therapeutics, which includes up to approximately USD 585 million in milestone payments and double-digit royalties on future net sales.<\/p>\n

Pozdeutinurad (AR882)<\/b> is a highly potent, selective next-generation urate transporter 1 (URAT1) inhibitor under development for gout treatment. It aims to lower serum urate, prevent flares, and resolve tophi. AR882 is currently in Phase III for chronic gout management and Phase II for refractory tophaceous gout. In Phase II trials, AR882 demonstrated superior efficacy over standard therapies, with the 75 mg dose reducing serum urate to <\/p>\n

In June 2025, Arthrosi Therapeutics<\/b> presented two studies at the EULAR Congress in Barcelona, emphasizing AR882\u2019s potential to reduce serum urate, prevent flares, and dissolve tophi in patients with gout and tophaceous gout. In March 2025, the company reported two major milestones in its Phase III program: early completion of enrollment in the pivotal global REDUCE 2 trial and dosing of the first patient in the replicate REDUCE 1 trial, both evaluating AR882\u2019s efficacy in lowering serum urate and resolving tophi. By December 2024, over 50% of patients had been enrolled in the REDUCE 2 trial. Additionally, AR882 received FDA Fast Track designation in August 2024 for the potential treatment of clinically visible tophi.<\/p>\n

ABP-671<\/b> is a once-daily oral URAT1 inhibitor that reduces uric acid reabsorption in the kidneys, increasing urinary excretion and lowering serum uric acid (sUA) levels. Long-term use can help dissolve tophi, prevent gout flares, and mitigate hyperuricemia-related complications, including cardiovascular, renal, and metabolic disorders. Clinical guidelines recommend maintaining serum uric acid (sUA) levels below 6 mg\/dL to prevent new crystal formation and below 5 mg\/dL to accelerate tophus resolution. In a Phase IIa trial, ABP-671 achieved these targets in 93% (Atom Therapeutics.<\/p>\n

In May 2025, Atom Therapeutics participated in the Gout Education Society\u2019s Gout Awareness Day to educate the public on gout risk factors and treatment options. Its lead candidate, lingdolinurad (ABP-671), is currently in Phase IIb\/III trials for chronic gout and hyperuricemia. In November 2024, Atom presented positive Phase I data at the ACR Convergence, showing ABP-671 was safe, well-tolerated, and effectively reduced serum uric acid in participants with mild to moderate chronic kidney disease. The therapy continues to advance in global Phase IIb\/III trials.<\/p>\n

The anticipated launch of these emerging chronic gout therapies are poised to transform the chronic gout market landscape in the coming years. As these cutting-edge chronic gout therapies continue to mature and gain regulatory approval, they are expected to reshape the chronic gout market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n

To know more about new treatment for chronic gout, visit @ Chronic Gout Management<\/b><\/a>\u00a0<\/b><\/p>\n

Recent Developments in the Chronic Gout Market<\/b><\/p>\n